- Home
- PNI vs TCRX Comparison
PNI vs TCRX Comparison
Compare PNI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- TCRX
- Stock Information
- Founded
- PNI 2002
- TCRX 2018
- Country
- PNI United States
- TCRX United States
- Employees
- PNI N/A
- TCRX N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- TCRX Health Care
- Exchange
- PNI Nasdaq
- TCRX Nasdaq
- Market Cap
- PNI 75.2M
- TCRX 82.1M
- IPO Year
- PNI N/A
- TCRX 2021
- Fundamental
- Price
- PNI $6.59
- TCRX $1.82
- Analyst Decision
- PNI
- TCRX Strong Buy
- Analyst Count
- PNI 0
- TCRX 6
- Target Price
- PNI N/A
- TCRX $9.50
- AVG Volume (30 Days)
- PNI 26.4K
- TCRX 619.4K
- Earning Date
- PNI 01-01-0001
- TCRX 08-11-2025
- Dividend Yield
- PNI 4.76%
- TCRX N/A
- EPS Growth
- PNI N/A
- TCRX N/A
- EPS
- PNI N/A
- TCRX N/A
- Revenue
- PNI N/A
- TCRX $4,421,000.00
- Revenue This Year
- PNI N/A
- TCRX $159.20
- Revenue Next Year
- PNI N/A
- TCRX N/A
- P/E Ratio
- PNI N/A
- TCRX N/A
- Revenue Growth
- PNI N/A
- TCRX N/A
- 52 Week Low
- PNI $6.03
- TCRX $1.02
- 52 Week High
- PNI $7.89
- TCRX $7.64
- Technical
- Relative Strength Index (RSI)
- PNI 35.55
- TCRX 57.99
- Support Level
- PNI $6.68
- TCRX $1.75
- Resistance Level
- PNI $6.78
- TCRX $1.94
- Average True Range (ATR)
- PNI 0.07
- TCRX 0.13
- MACD
- PNI -0.01
- TCRX 0.02
- Stochastic Oscillator
- PNI 9.52
- TCRX 77.78
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.